

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

SHARE AWARD SCHEME
INCREASE OF INDIVIDUAL LIMIT

Reference is made to the announcement of Kingworld Medicines Group Limited (the “**Company**”) dated 27 August 2019 in relation to the adoption of the Share Award Scheme by the Company (the “**Announcement**”), the announcement of the Company dated 22 May 2020 in relation to the increase of scheme limit and the announcement of the Company dated 21 January 2022 in relation to the grant of award pursuant to the Share Award Scheme. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

INCREASE OF INDIVIDUAL LIMIT OF THE SHARE AWARD SCHEME

As disclosed in the Announcement, the purposes of the Share Award Scheme are to recognise the contributions by certain Participants and to provide incentives in retaining the Participants for the continual operation and development of the Group and to attract suitable personnel for further development of the Group.

Pursuant to the Share Award Scheme, the maximum number of Shares which may be allocated and awarded to a Selected Participant under the Share Award Scheme in any 12-month period shall not exceed 0.01% of the issued share capital of the Company immediately preceding such allocation and award (the “**Individual Limit**”).

In order to provide further incentives for the Participants, the Board is pleased to announce that it has resolved to increase the Individual Limit from 0.01% to 0.1% of the issued share capital of the Company immediately preceding such allocation and award (the “**Increased Individual Limit**”) with effect from 29 March 2022.

Apart from the Increased Individual Limit, there is no change on the Share Award Scheme.

The Board will from time to time review and determine at its absolute discretion such number of Shares to be awarded to the Selected Participants with such vesting conditions as it may deem appropriate and the number of Shares to be purchased by the Trustee from the market under the Share Award Scheme.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 29 March 2022

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.